Traditional MedicareCoverageHigh impact
MolDX: Molecular Testing for Solid Organ Allograft Rejection
Medicare/CMS - LCD·Transplant Surgery, Nephrology·Local Coverage Determination
We identified it
Sep 3, 2026
Summary
This policy (L38568) for molecular testing in solid organ allograft rejection has been RETIRED as of 8/29/2026. This is a coverage determination that is no longer active. Billing teams should immediately stop applying this policy guidance and verify current coverage requirements with Palmetto GBA or consult the CMS Medicare Coverage Database for any replacement policies.
Action Required
Immediately: Billing team must verify the current status of molecular testing coverage for solid organ allograft rejection with Palmetto GBA (MAC Part A and Part B). Do NOT use LCD L38568 (retired 8/29/2026) for any new claims. Search the CMS Medicare Coverage Database for replacement or successor policies. Contact compliance officer to audit any claims submitted under this retired policy in the last 90 days for potential recovery/correction. Update internal policy documentation to reflect retirement status.